Nasal administration of CTB-insulin induces active tolerance against autoimmune diabetes in non-obese diabetic (NOD) mice

Clinical and Experimental Immunology

Volumn 130, Issue 2, 2002, Pages 204-211

  Aspord, C ^a   Thivolet, C ^a  

^a INSERM   (France)

Author keywords

CTB insulin; Diabetes; Nasal tolerance; NOD mice

Indexed keywords

ANTIGEN; CD4 ANTIGEN; CHOLERA TOXIN B SUBUNIT; GAMMA INTERFERON; INSULIN; INTERLEUKIN 10; INTERLEUKIN 4; RNA; TRANSFORMING GROWTH FACTOR BETA;

ANALYSIS; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; BETA CHAIN; CELL PROLIFERATION; CONJUGATE; DIABETES MELLITUS; DIABETOGENESIS; FEMALE; IMMUNIZATION; IN VITRO STUDY; LYMPH NODE; LYMPHOCYTIC INFILTRATION; MALE; MORBIDITY; MOUSE; NONHUMAN; NOSE MUCOSA; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN; SPLEEN CELL; T LYMPHOCYTE;

EID: 0036408394     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2002.01988.x     Document Type: Article

References (40)

1. Bach JF. Insulin-dependent diabetes mellitus as an autoimmune disease. Endocr Rev 1994;15:516-42.
2. Cahill GF Jr, McDevitt HO. Insulin-dependent diabetes mellitus: The initial lesion. N Engl J Med 1981;304:1454-65.
3. Kishimoto H, Sprent J. A defect in central tolerance in NOD mice. Nat Immunol 2001;2:1025-31.
4. Ridgway WM, Fasso M, Lanctot A, Garvey C, Fathman CG. Breaking self-tolerance in nonobese diabetic mice. J Exp Med 1996;183:1657-62.
5. Xiao BG, Link H. Mucosal tolerance: A two-edged sword to prevent and treat autoimmune diseases. Clin Immunol Immunopathol 1997; 85:119-28.
6. Bai XF, Link H. Nasal tolerance induction as a potential means of immunotherapy for autoimmune diseases: Implications for clinical medicine. Clin Exp Allergy 2000;30:1688-96.
7. Higuchi K, Kweon MN, Fujihashi K, McGhee JR, Kiyono H. Comparison of nasal and oral tolerance for the prevention of collagen induced murine arthritis. J Rheumatol 2000;27:1038-44.
8. Kuper CF, Koornstra PJ, Hameleers DM et al. The role of nasopharyngeal lymphoid tissue. Immunol Today 1992;13:219-24.
9. Metzler B, Wraith DC. Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: Influence of MHC binding affinity. Int Immunol 1993;5:1159-65.
10. Li HL, Liu JQ, Bai XF, van der Meide PH, Link H. Dose-dependent mechanisms relate to nasal tolerance induction and protection against experimental autoimmune encephalomyelitis in Lewis rats. Immunology 1998;94:431-7.
11. al-Sabbagh A, Nelson PA, Akselband Y, Sobel RA, Weiner HL. Antigen-driven peripheral immune tolerance. suppression of experimental autoimmmune encephalomyelitis and collagen-induced arthritis by aerosol administration of myelin basic protein or type II collagen. Cell Immunol 1996;171:111-9.
12. Im S, Barchan D, Fuchs S, Souroujon MC. Mechanism of nasal tolerance induced by a recombinant fragment of acetylcholine receptor for treatment of experimental myasthenia gravis. J Neuroimmunol 2000; 111:161-8.
13. Barchan D, Souroujon MC, Im SH, Antozzi C, Fuchs S. Antigen-specific modulation of experimental myasthenia gravis: Nasal tolerization with recombinant fragments of the human acetylcholine receptor alpha-subunit. Proc Natl Acad Sci USA 1999;96:8086-91.
14. Shi FD, Li H, Wang H et al. Mechanisms of nasal tolerance induction in experimental autoimmune myasthenia gravis: Identification of regulatory cells. J Immunol 1999;162:5757-63.
15. Garcia G, Komagata Y, Slavin AJ, Maron R, Weiner HL. Suppression of collagen-induced arthritis by oral or nasal administration of type II collagen. J Autoimmun 1999;13:315-24.
16. Chu CQ, Londei M. Differential activities of immunogenic collagen type II peptides in the induction of nasal tolerance to collagen-induced arthritis. J Autoimmun 1999;12:35-42.
17. Maron R, Melican NS, Weiner HL. Regulatory Th2-type T cell lines against insulin and GAD peptides derived from orally- and nasally-treated NOD mice suppress diabetes. J Autoimmun 1999;12:251-8.
18. Harrison LC, Dempsey-Collier M, Kramer DR, Takahashi K. Aerosol insulin induces regulatory CD8 gamma delta T cells that prevent murine insulin-dependent diabetes. J Exp Med 1996; 184:2167-74.
19. Ramiya VK, Shang XZ, Wasserfall CH, Maclaren NK. Effect of oral and intravenous insulin and glutamic acid decarboxylase in NOD mice. Autoimmunity 1997;26:139-51.
20. Tian J, Atkinson MA, Clare-Salzler M et al. Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J Exp Med 1996; 183:1561-7.
21. Daniel D, Wegmann DR. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc Natl Acad Sci USA 1996;93:956-60.
22. Hanninen A, Harrison LC. Gamma delta T cells as mediators of mucosal tolerance: The autoimmune diabetes model. Immunol Rev 2000;173:109-19.
23. Bergerot I, Ploix C, Petersen J et al. A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes. Proc Natl Acad Sci USA 1997;94:4610-4.
24. Ploix C, Bergerot I, Fabien N, Perche S, Moulin V, Thivolet C. Protection against autoimmune diabetes with oral insulin is associated with the presence of IL-4 type 2 T-cells in the pancreas and pancreatic lymph nodes. Diabetes 1998;47:39-44.
25. Metzler B, Wraith DC. Inhibition of T-cell responsiveness by nasal peptide administration: Influence of the thymus and differential recovery of T-cell-dependent functions. Immunology 1999;97:257-63.
26. Metzler B, Anderton SM, Manickasingham SP, Wraith DC. Kinetics of peptide uptake and tissue distribution following a single intranasal dose of peptide. Immunol Invest 2000;29:61-70.
27. + regulatory T-cells. Diabetes 1999;48:2150-6.
28. Sun JB, Holmgren J, Czerkinsky C. Cholera toxin B subunit: An efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance. Proc Natl Acad Sci USA 1994;91:10795-9.
29. Porgador A, Staats HF, Itoh Y, Kelsall BL. Intranasal immunization with cytotoxic T-lymphocyte epitope peptide and mucosal adjuvant cholera toxin: Selective augmentation of peptide-presenting dendritic cells in nasal mucosa-associated lymphoid tissue. Infect Immun 1998; 66:5876-81.
30. Yingzi C, Weaver CT, Elson CO. The mucosal adjuvanticity of cholera toxin involves enhancement of costimulatory activity by selective up-regulation of B7.2 expression. J Immunol 1997;159:5301-8.
31. Gagliardi MC, Sallusto F, Marinaro M, Langenkamp A, Lanzavecchia A, De Magistris MT. Cholera toxin induces maturation of human dendritic cells and licences them for Th2 priming. Eur J Immunol 2000; 30:2394-403.
32. Braun MC, He J, Wu CY, Kelsall BL. Cholera toxin suppresses interleukin (IL)-12 production and IL-12 receptor beta1 and beta2 chain expression. J Exp Med 1999;189:541-52.
33. Marinaro M, Staats HF, Hiroi T et al. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J Immunol 1995;155:4621-9.
34. Xiao BG, Zhang GX, Shi FD, Ma CG, Link H. Decrease of LFA-1 is associated with upregulation of TGF-beta in CD4 (+) T cell clones derived from rats nasally tolerized against experimental autoimmune myasthenia gravis. Clin Immunol Immunopathol 1998;89:196-204.
35. Prange S, Zucker P, Jevnikar AM, Singh B. Transplanted MHC class I-deficient nonobese diabetic mouse islets are protected from autoimmune injury in diabetic nonobese recipients. Transplantation 2001; 71:982-5.
36. Kweon MN, Fujihashi K, VanCott JL et al. Lack of orally induced systemic unresponsiveness in IFN-gamma knockout mice. J Immunol 1998;160:1687-93.
37. + T cells precedes the development of tolerance in vivo. Int Immunol 1996;8:335-42.
38. Jiang HR, Taylor N, Duncan L, Dick AD, Forrester JV. Total dose and frequency of administration critically affect success of nasal mucosal tolerance induction. Br J Ophthalmol 2001;85:739-44.
39. Hanninen A, Braakhuis A, Heath WR, Harrison LC. Mucosal antigen primes diabetogenic cytotoxic T-lymphocytes regardless of dose or delivery route. Diabetes 2001;50:771-5.
40. Bai XF, Li HL, Shi FD et al. Complexities of applying nasal tolerance induction as a therapy for ongoing relapsing experimental autoimmune encephalomyelitis (EAE) in DA rats. Clin Exp Immunol 1998; 111:205-10.